Amylin Pharmaceuticals Inc. and partner Eli Lilly and Co. filed a new drug application seeking approval of exenatide as a treatment for Type II diabetes. (BioWorld Today)

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Novartis to pay $1.5B for Myricx Bio and its novel ADC payloads
BioWorld
Novartis AG is to pay $1.1 billion up front to acquire Myricx Bio Ltd., a preclinical-stage antibody-drug conjugate (ADC) specialist that is advancing a novel and...

Medical technology RSS

Medical technology
RSS